Clinical trial

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruiting · Phase 3 · 3 countries · Registry ID NCT06859268

Active, not recruitingPhase 3Interventional

What this study is about

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity

Full registry criteria

Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Treatments and study arms

Retatrutide

Drug

Administered SC

Placebo

Drug

Administered SC

Primary outcomes

Percent Change from Baseline in Body WeightWeek 0, Week 116

Study locations

53 locations were listed when this page was built. The first 40 are shown.

Aggarwal and Associates Limited🇨🇦 Brampton, Canada